{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T15:23:14Z","timestamp":1761578594233,"version":"3.41.0"},"reference-count":42,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"32","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1097\/md.0000000000001067","type":"journal-article","created":{"date-parts":[[2015,8,11]],"date-time":"2015-08-11T20:02:39Z","timestamp":1439323359000},"page":"e1067","source":"Crossref","is-referenced-by-count":8,"title":["Bivalirudin Anticoagulant Therapy With or Without Platelet Glycoprotein IIb\/IIIa Inhibitors During Transcatheter Coronary Interventional Procedures"],"prefix":"10.1097","volume":"94","author":[{"given":"Jiabei","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiyong","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dehui","family":"Qian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-3-20210226","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1177\/107424840501000401","article-title":"Bivalirudin vs heparin in percutaneous coronary intervention: a pooled analysis","volume":"10","author":"Ebrahimi","year":"2005","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"R2-3-20210226","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.amjcard.2012.03.051","article-title":"Meta-analysis comparing bivalirudin versus heparin monotherapy on ischemic and bleeding outcomes after percutaneous coronary intervention","volume":"110","author":"Bertrand","year":"2012","journal-title":"Am J Cardiol"},{"key":"R3-3-20210226","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1177\/2048872613514013","article-title":"Efficacy and safety of tirofiban-supported primary percutaneous coronary intervention in patients pretreated with 600\u200amg clopidogrel: results of propensity analysis using the Clinical Center of Serbia STEMI Register","volume":"3","author":"Mrdovic","year":"2014","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"R4-3-20210226","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1177\/1753944713487781","article-title":"Update on platelet glycoprotein IIb\/IIIa inhibitors: recommendations for clinical practice","volume":"7","author":"Muniz-Lozano","year":"2013","journal-title":"Ther Adv Cardiovasc Dis"},{"key":"R5-3-20210226","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1016\/j.amjcard.2013.02.020","article-title":"Safety and efficacy of adjuvant glycoprotein IIb\/IIIa inhibitors during primary percutaneous coronary intervention performed from the radial approach for acute ST segment elevation myocardial infarction","volume":"111","author":"Iqbal","year":"2013","journal-title":"Am J Cardiol"},{"key":"R6-3-20210226","doi-asserted-by":"crossref","first-page":"401.e6","DOI":"10.1016\/j.ahj.2013.11.013","article-title":"Impact of baseline hemorrhagic risk on the benefit of bivalirudin versus unfractionated heparin in patients treated with coronary angioplasty: a meta-regression analysis of randomized trials","volume":"167","author":"Tarantini","year":"2014","journal-title":"Am Heart J"},{"key":"R7-3-20210226","doi-asserted-by":"crossref","first-page":"196","DOI":"10.4244\/EIJY14M08_01","article-title":"Bivalirudin versus heparin in patients treated with percutaneous coronary intervention: a meta-analysis of randomised trials","volume":"11","author":"Cassese","year":"2015","journal-title":"EuroIntervention"},{"key":"R8-3-20210226","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/S0140-6736(14)61216-2","article-title":"Bivalirudin versus heparin in patients planned for percutaneous coronary intervention: a meta-analysis of randomised controlled trials","volume":"384","author":"Cavender","year":"2014","journal-title":"Lancet"},{"key":"R9-3-20210226","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1161\/CIRCINTERVENTIONS.113.001126","article-title":"Heparin monotherapy or bivalirudin during percutaneous coronary intervention in patients with non-ST-segment-elevation acute coronary syndromes or stable ischemic heart disease: results from the Evaluation of Drug-Eluting Stents and Ischemic Events registry","volume":"7","author":"Bangalore","year":"2014","journal-title":"Circ Cardiovasc Interv"},{"key":"R10-3-20210226","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(14)60924-7","article-title":"Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial","volume":"384","author":"Shahzad","year":"2014","journal-title":"Lancet"},{"key":"R11-3-20210226","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.3760\/cma.j.issn.0366-6999.20122569","article-title":"Evaluation on the efficacy and safety of domestic bivalirudin during percutaneous coronary intervention","volume":"126","author":"Xiang","year":"2013","journal-title":"Chin Med J (Engl"},{"key":"R12-3-20210226","doi-asserted-by":"crossref","first-page":"430","DOI":"10.4244\/EIJV9I4A71","article-title":"One-year outcomes with abciximab and unfractionated heparin versus bivalirudin during percutaneous coronary interventions in patients with non-ST-segment elevation myocardial infarction: updated results from the ISAR-REACT 4 trial","volume":"9","author":"Schulz","year":"2013","journal-title":"EuroIntervention"},{"key":"R13-3-20210226","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Control Clin Trials"},{"key":"R14-3-20210226","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/j.amjcard.2011.06.035","article-title":"Meta-analysis of early versus deferred revascularization for non-ST-segment elevation acute coronary syndrome","volume":"108","author":"Zhang","year":"2011","journal-title":"Am J Cardiol"},{"key":"R15-3-20210226","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.2307\/2533446","article-title":"Operating characteristics of a rank correlation test for publication bias","volume":"50","author":"Begg","year":"1994","journal-title":"Biometrics"},{"key":"R16-3-20210226","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1016\/S0140-6736(99)04149-5","article-title":"Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses","volume":"354","author":"Moher","year":"1999","journal-title":"Lancet"},{"key":"R17-3-20210226","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1056\/NEJMoa062437","article-title":"Bivalirudin for patients with acute coronary syndromes","volume":"355","author":"Stone","year":"2006","journal-title":"N Engl J Med"},{"key":"R18-3-20210226","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1001\/jama.298.21.2497","article-title":"Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: one-year results from the ACUITY trial","volume":"298","author":"Stone","year":"2007","journal-title":"JAMA"},{"key":"R19-3-20210226","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.amjcard.2012.04.017","article-title":"Comparison of safety and efficacy of bivalirudin versus unfractionated heparin in high-risk patients undergoing percutaneous coronary intervention (from the Anti-Thrombotic Strategy for Reduction of Myocardial Damage During Angioplasty-Bivalirudin vs Heparin study)","volume":"110","author":"Patti","year":"2012","journal-title":"Am J Cardiol"},{"key":"R20-3-20210226","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.amjcard.2009.12.001","article-title":"Comparison of bivalirudin and unfractionated heparin plus protamine in patients with coronary heart disease undergoing percutaneous coronary intervention (from the Antithrombotic Regimens aNd Outcome [ARNO] trial)","volume":"105","author":"Parodi","year":"2010","journal-title":"Am J Cardiol"},{"key":"R21-3-20210226","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1067\/mhj.2001.119374","article-title":"Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: final report reanalysis of the Bivalirudin Angioplasty Study","volume":"142","author":"Bittl","year":"2001","journal-title":"Am Heart J"},{"key":"R22-3-20210226","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1067\/mhj.2002.122173","article-title":"Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial (CACHET)","volume":"143","author":"Lincoff","year":"2002","journal-title":"Am Heart J"},{"key":"R23-3-20210226","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1056\/NEJMoa0708191","article-title":"Bivalirudin during primary PCI in acute myocardial infarction","volume":"358","author":"Stone","year":"2008","journal-title":"N Engl J Med"},{"key":"R24-3-20210226","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1016\/S0140-6736(11)60764-2","article-title":"Heparin plus a glycoprotein IIb\/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial","volume":"377","author":"Stone","year":"2011","journal-title":"Lancet"},{"key":"R25-3-20210226","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1056\/NEJMoa0802944","article-title":"Bivalirudin versus unfractionated heparin during percutaneous coronary intervention","volume":"359","author":"Kastrati","year":"2008","journal-title":"N Engl J Med"},{"key":"R26-3-20210226","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1093\/eurheartj\/ehq008","article-title":"Bivalirudin vs. unfractionated heparin during percutaneous coronary interventions in patients with stable and unstable angina pectoris: 1-year results of the ISAR-REACT 3 trial","volume":"31","author":"Schulz","year":"2010","journal-title":"Eur Heart J"},{"key":"R27-3-20210226","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1056\/NEJMoa1109596","article-title":"Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction","volume":"365","author":"Kastrati","year":"2011","journal-title":"N Engl J Med"},{"key":"R28-3-20210226","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/j.amjcard.2009.06.035","article-title":"Comparison of bivalirudin monotherapy versus unfractionated heparin plus tirofiban in patients with diabetes mellitus undergoing elective percutaneous coronary intervention","volume":"104","author":"Tavano","year":"2009","journal-title":"Am J Cardiol"},{"key":"R29-3-20210226","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1016\/j.jacc.2005.12.077","article-title":"A randomized trial to evaluate the relative protection against post-percutaneous coronary intervention microvascular dysfunction, ischemia, and inflammation among antiplatelet and antithrombotic agents: the PROTECT-TIMI-30 trial","volume":"47","author":"Gibson","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"R30-3-20210226","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.amjcard.2004.01.033","article-title":"Comparison of bivalirudin versus heparin during percutaneous coronary intervention (the Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events [REPLACE]-1 trial)","volume":"93","author":"Lincoff","year":"2004","journal-title":"Am J Cardiol"},{"key":"R31-3-20210226","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1001\/jama.289.7.853","article-title":"Bivalirudin and provisional glycoprotein IIb\/IIIa blockade compared with heparin and planned glycoprotein IIb\/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial","volume":"289","author":"Lincoff","year":"2003","journal-title":"JAMA"},{"key":"R32-3-20210226","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1001\/jama.292.6.696","article-title":"Long-term efficacy of bivalirudin and provisional glycoprotein IIb\/IIIa blockade vs heparin and planned glycoprotein IIb\/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial","volume":"292","author":"Lincoff","year":"2004","journal-title":"JAMA"},{"key":"R33-3-20210226","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1002\/ccd.22876","article-title":"A randomized two-by-two comparison of high-dose bolus tirofiban versus abciximab and unfractionated heparin versus bivalirudin during percutaneous coronary revascularization and stent placement: the tirofiban evaluation of novel dosing versus abciximab with clopidogrel and inhibition of thrombin (TENACITY) study trial","volume":"77","author":"Moliterno","year":"2011","journal-title":"Catheter Cardiovasc Interv"},{"key":"R34-3-20210226","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.jacc.2008.05.036","article-title":"Safety and efficacy of bivalirudin with and without glycoprotein IIb\/IIIa inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention 1-year results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial","volume":"52","author":"White","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"R35-3-20210226","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.jcin.2014.10.015","article-title":"Novel Approaches for Preventing or Limiting Events (Naples) III Trial: randomized comparison of bivalirudin versus unfractionated heparin in patients at increased risk of bleeding undergoing transfemoral elective coronary stenting","volume":"8","author":"Briguori","year":"2015","journal-title":"JACC Cardiovasc Interv"},{"key":"R36-3-20210226","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa1311096","article-title":"Bivalirudin started during emergency transport for primary PCI","volume":"369","author":"Steg","year":"2013","journal-title":"N Engl J Med"},{"key":"R37-3-20210226","doi-asserted-by":"crossref","first-page":"44","DOI":"10.2174\/1871525711311010008","article-title":"The clinical utility of bivalirudin in patients with coronary artery disease","volume":"11","author":"Garner","year":"2013","journal-title":"Cardiovasc Hematol Agents Med Chem"},{"key":"R38-3-20210226","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1517\/14740338.2012.628312","article-title":"Safety of bivalirudin in patients with coronary artery disease","volume":"11","author":"Abdel-Wahab","year":"2012","journal-title":"Expert Opin Drug Saf"},{"key":"R39-3-20210226","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1016\/j.jacc.2009.09.076","article-title":"A risk score to predict bleeding in patients with acute coronary syndromes","volume":"55","author":"Mehran","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"R40-3-20210226","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.jcin.2011.02.011","article-title":"Impact of bleeding on mortality after percutaneous coronary intervention results from a patient-level pooled analysis of the REPLACE-2 (randomized evaluation of PCI linking angiomax to reduced clinical events), ACUITY (acute catheterization and urgent intervention triage strategy), and HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trials","volume":"4","author":"Mehran","year":"2011","journal-title":"JACC Cardiovasc Interv"},{"key":"R41-3-20210226","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N Engl J Med"},{"key":"R42-3-20210226","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000001067","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T23:37:22Z","timestamp":1748561842000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201508020-00003"}},"subtitle":["A Meta-Analysis"],"short-title":[],"issued":{"date-parts":[[2015,8]]},"references-count":42,"journal-issue":{"issue":"32","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000001067","relation":{},"ISSN":["0025-7974"],"issn-type":[{"type":"print","value":"0025-7974"}],"subject":[],"published":{"date-parts":[[2015,8]]}}}